Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.

Participants needed: 316
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Aug 4, 2026Locations: 1
Eligibility criteria

Expected survival of ≥ 3 months. [+6]

Trial participants with known deficient mismatch repair/microsatellite instabili... [+10]

Read more
Status: Recruiting

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).

Participants needed: 160
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Jul 28, 2026Locations: 8
Eligibility criteria

Able to understand and provide written informed consent, and comply with the req... [+9]

Prior histologically/cytologically confirmed diagnosis of hepatocellular carcino... [+14]

Read more
Status: Recruiting

Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

A multicenter, randomized, double-blind, phase II clinical study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Becotatug Vedotin for Injection in combination with PD-1 in patients with locally advanced resectable head and neck squamous cell carcinoma

Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Jul 9, 2026Locations: 15
Eligibility criteria

Life expectancy ≥ 6 months. [+7]

Primary tumor originating from nasopharynx, nasal cavity, paranasal sinuses, sal... [+25]

Read more
Status: Not yet recruiting

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.

Participants needed: 231
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: May 15, 2026Locations: 1
Eligibility criteria

Willing to sign the informed consent form and follow the requirements specified... [+5]

History of other primary malignant tumors [+20]

Read more
Status: Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.

Participants needed: 16
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Apr 23, 2026Locations: 14
Eligibility criteria

Be ≥18 years of age on day of signing informed consent. [+5]

Has current or past history of muscle invasive (T2 or higher stage) or locally a... [+5]

Read more
Status: Recruiting

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.

Participants needed: 343
Trial details
Phase: Phase 1, Phase 2Age: 17-85Biological sex: AllType: InterventionalSponsor: Lepu Biopharma Co., Ltd.Updated: Jan 22, 2026Locations: 2
Eligibility criteria

Understand and provide written informed consent and comply with the requirements... [+9]

Moderate and above thoracoabdominal pelvic fluid and pericardial effusion with c... [+19]

Read more